Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 471

Sort by

Sort Order Select

Journal Articles

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Blood (2021) 137 (23): 3272–3276.

https://doi.org/10.1182/blood.2020008865

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

Fraser Soares, Branson Chen, Jong Bok Lee, Musaddeque Ahmed, Dalam Ly, Enoch Tin, Hyeonjeong Kang, Yong Zeng, Nayeema Akhtar, Mark D. Minden, Housheng Hansen He, Li Zhang

Blood (2021) 137 (16): 2171–2181.

https://doi.org/10.1182/blood.2019004108

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

Virus-specific T-cell therapies for patients with primary immune deficiency

Michael D. Keller, Catherine M. Bollard

Blood (2020) 135 (9): 620–628.

https://doi.org/10.1182/blood.2019000924

Published: 2020

Journal Articles

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong

Blood (2020) 135 (5): 387–391.

https://doi.org/10.1182/blood.2019003293

Published: 2020

Includes: Supplemental data

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Xin Li, Rui Zhang, Qing Li, Juan Mu, Yedi Pu, Yili Jiang, Qi Deng

Blood (2019) 134 (Supplement_1): 5357.

https://doi.org/10.1182/blood-2019-128035

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1603.

https://doi.org/10.1182/blood-2019-125162

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 2199.

https://doi.org/10.1182/blood-2019-131533

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

Automation Platform for CAR-T Manufacturing: The Benefits and the Clinical Outcomes

Min Wang, PhD, Fengtao You, PhD, Xingbing Wang, MD, Bingzong Li, MD PhD, Hanying Xu, MS, Yu Wang, MS, Guifang Pan, MS, Song Sun, MS, Huimin Meng, MD PhD, Yanmei Zhao, MS, Yu-Sheng Chen, PhD, Bozhen Zhang, MBA, Lin Yang, PhD

Blood (2019) 134 (Supplement_1): 1960.

https://doi.org/10.1182/blood-2019-123656

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Virus-specific T-cell therapies for patients with primary immune deficiency

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Automation Platform for CAR-T Manufacturing: The Benefits and the Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only